Premium
Upregulation of PRKD1 gene expression by activated K‐ras in pancreatic cancer cells (609.20)
Author(s) -
Storz Peter,
Doeppler Heike
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.609.20
Subject(s) - downregulation and upregulation , cancer research , transcription factor , gene , pancreatic cancer , promoter , oncogene , biology , kinase , nf κb , signal transduction , cancer , gene expression , chemistry , microbiology and biotechnology , genetics , cell cycle
Summary Activating mutations of the K‐ras proto‐oncogene are detected in over 95% of pancreatic adenocarcinoma (PDA) and its precursor lesions. One mechanism by which activated K‐ras can drive the development of PDA is activation of the transcription factor nuclear factor κ‐B (NF‐κB), which has been shown to regulate genes involved in all aspects of tumor formation and progression. We here describe the PRKD1 gene promoter as a target for K‐ras‐NF‐κB signaling. We identify the binding sites for NF‐κB in the PRKD1 promoter and show that K‐ras‐driven upregulation of expression of PRKD1 and its gene product protein kinase D1 (PKD1) is linked to increased cell survival and oncogenic signaling in PDA. Conclusion Our data provide a functional link between oncogenic K‐ras, NF‐κB and PKD1, a targetable kinase in this cancer. Grant Funding Source : Supported by the NCI R01 grant CA140182